Cancers, Vol. 11, Pages 1189: How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
Cancers, Vol. 11, Pages 1189: How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
Cancers doi: 10.3390/cancers11081189
Authors:
Galvano
Incorvaia
Badalamenti
Rizzo
Guarini
Cusenza
Castellana
Barraco
Calò
Cutaia
Currò
Silvestris
Beretta
Bazan
Russo
Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) have demonstrated efficacy with chemotherapy (CT) as second line treatment for metastatic colorectal cancer (mCRC). The right sequence of the treatments in all RAS (KRAS/NRAS) wild type (wt) patients has not precisely defined. We evaluated the impact of aforementioned targeted therapies in second line setting, analyzing efficacy and safety data from phase III clinical trials. We performed both direct and indirect comparisons between anti-EGFR and anti-VEGF. Outcomes included disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and G3-G5 toxicities. Our results showed significantly improved OS (HR 0.83, 95% CI 0.72–0.94) and DCR (HR 1.27, 95% CI 1.04–1.54) favouring anti-VEGF combinations in overall population; no statistically significant differences in all RAS wt patients was observed (HR 0.87, 95% CI 0.70–1.09). Anti-EGFR combinations significantly increased ORR in all patients (RR 0.54, 95% CI 0.31&...
Source: Cancers - Category: Cancer & Oncology Authors: Galvano Incorvaia Badalamenti Rizzo Guarini Cusenza Castellana Barraco Cal ò Cutaia Curr ò Silvestris Beretta Bazan Russo Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Colorectal Cancer | Statistics | Toxicology